Deirdre O'Hanlon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deirdre O'Hanlon has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- David O'REilly
Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland
2 shared publications - Julie McCarthy
Department of Histopathology, South Infirmary Victoria University Hospital, Cork, Ireland
2 shared publications - Killian Nugent
Department of Radiotherapy, Cork University Hospital, Cork, Ireland
2 shared publications - Linda Feeley
Department of Pathology Cork University Hospital Cork Ireland
2 shared publications - Orla O'Mahony
Department of Histopathology, South Infirmary Victoria University Hospital, Cork, Ireland
2 shared publications - Patrick Sheahan
ENTO Research Unit, School of Medicine and Health, University College Cork, Cork, Ireland
2 shared publications
Latest Publications
- Open Access
Visceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas
Anaplastic thyroid cancer (ATC) is considered to be one of the most virulent, treatment-refractory malignancies. Recent molecular insights into the biology of thyroid cancer have transformed ATC management, and BRAF/MEK targeted therapy is now incorporated into guideline-based multidisciplinary care. We report visceral perforation in the setting of an extreme response to such therapy in a patient with ATC. Molecularly targeted therapy afforded a dramatic but life-threatening response to treatment. This report highlights the complexities of care for the patient and treating clinicians.
Open AccessVisceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas
Anaplastic thyroid cancer (ATC) is considered to be one of the most virulent, treatment-refractory malignancies. Recent molecular insights into the biology of thyroid cancer have transformed ATC management, and BRAF/MEK targeted therapy is now incorporated into guideline-based multidisciplinary care. We report visceral perforation in the setting of an extreme response to such therapy in a patient with ATC. Molecularly targeted therapy afforded a dramatic but life-threatening response to treatment. This report highlights the complexities of care for the patient and treating clinicians.
- Open Access
- 4 October 2024
- Published by MDPI AG in Preprints.org
Visceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas
Anaplastic thyroid cancer (ATC) is considered to be one of the most virulent, treatment refractory, malignancies. Recent molecular insights into the biology of thyroid cancer have transformed ATC management and BRAF/MEK targeted therapy is now incorporated into guideline based multidisciplinary care. We report visceral perforation in the setting of an extreme response to such therapy in a patient with a mixed papillary thyroid carcinoma and ATC. Molecularly targeted therapy afforded a dramatic, but life-threatening, response to treatment. This report highlights the complexities of care for the patient and treating clinicians.
- 4 October 2024
- Published by MDPI AG in Preprints.org
Open AccessVisceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas
Anaplastic thyroid cancer (ATC) is considered to be one of the most virulent, treatment refractory, malignancies. Recent molecular insights into the biology of thyroid cancer have transformed ATC management and BRAF/MEK targeted therapy is now incorporated into guideline based multidisciplinary care. We report visceral perforation in the setting of an extreme response to such therapy in a patient with a mixed papillary thyroid carcinoma and ATC. Molecularly targeted therapy afforded a dramatic, but life-threatening, response to treatment. This report highlights the complexities of care for the patient and treating clinicians.